US SEC Trading Suspension Halt Orders — May 20, 2026

Regained Nasdaq compliance within 16 days of deficiency notice by appointing an independent director; this rapid resolution suggests strong governance and board responsiveness, with the deficiency resolved at minimal cost

Received a second 180-day extension from Nasdaq, indicating the exchange is granting leniency; however, this is the company's second extension with no visible progress on bid price—management has not executed a reverse split nor reported insider buying, suggesting a low-probability recovery

Received a delisting notice for failing both the minimum bid price ($1.00) AND stockholders' equity ($2.5M) requirements simultaneously; the dual deficiency significantly reduces the likelihood of a successful appeal, as curing one metric alone still leaves the other unmet

Filed Chapter 11 bankruptcy 2 days before the delisting notice; the bankruptcy effectively renders the equity worthless for common shareholders, with delisting serving as the final formal step—a liquidation scenario is the base case

Has until November 16, 2026 (180 days) to cure the bid price deficiency; the stock continues trading on Nasdaq under SCKT, providing a speculative catalyst if the company executes a reverse split or announces positive operational changes [NEUTRAL-to-BULLISH if catalysts emerge]

Only 60 days to file the delinquent 10-Q or submit a compliance plan; this is a special purpose acquisition company (SPAC) with no operating revenue—the filing delay could signal problems finding an acquisition target or issues with sponsor funding

0 of 6 companies reported ANY insider buying or selling activity in the enriched data, despite 5 of 6 facing negative compliance events; this absence of insider transactions suggests management either lacks confidence to buy or is restricted due to bankruptcy/blackout periods, a bearish signal in aggregate

4 of 6 companies (SOCIETY PASS, TOMI, Singularity Future, Socket Mobile) have been non-compliant for over 6 months based on initial notice dates in November 2025; the persistence of non-compliance indicates structural issues rather than temporary market dislocations, reducing the probability of successful cures

Chapter 11 filing on May 12, 2026, followed by Nasdaq delisting effective May 21, 2026; common equity holders are last in priority and face total loss—heightened risk that the stock becomes worthless within days

Failed BOTH bid price ($1.00) and stockholders' equity ($2.5M) requirements; even if TOMI appeals and wins a stay, curing both deficiencies simultaneously within the stay period is highly unlikely without a major capital infusion, which may dilute existing shareholders

Received a second 180-day extension to November 16, 2026, after failing to cure during the first extension (Nov 2025-May 2026); this pattern suggests the company is unable to maintain the bid price even temporarily, making the next deadline likely a delisting event

Has 180 days to cure, but the stock has traded below $1.00 for at least 30 consecutive days as of May 19, 2026; if the stock continues its downward trajectory, the cure probability diminishes each week, with delisting risk increasing after November 2026

Failure to file the 10-Q by May 15, 2026, triggers a 60-day cure period; as a SPAC with no operating business, the company has no internal revenue to generate cash for filing costs, and the delayed filing could indicate sponsor disputes or inability to close a de-SPAC merger, leading to liquidation

With delisted or at-risk stocks, broker-dealers may reduce market-making activity, widening bid-ask spreads and limiting institutional investment; this liquidity vacuum can accelerate price declines, creating a negative feedback loop that makes bid price compliance harder to achieve

The companies plan to appeal delisting (SOCIETY PASS, TOMI) or have received extensions (Singularity); however, appeals historically have a low success rate for companies with fundamental compliance failures (bankruptcy, dual deficiencies), and the appeal process can consume management attention and legal fees without changing outcomes

Company regained compliance with minimal disruption—the stock did not face suspension risk, and the rapid resolution (16 days) signals strong board governance; for investors seeking micro-cap exposure with lower regulatory risk, Innventure represents a positive outlier in this stream

With 180 days to cure the bid price deficiency, Socket Mobile may execute a reverse stock split to boost the share price above $1.00; historical patterns show micro-cap companies often announce splits 60-90 days before the deadline, creating a potential share price appreciation catalyst if accompanied by positive operational news

The second 180-day extension (through November 16, 2026) provides a defined window for a speculative turnaround; if the company announces a reverse split, asset sale, or new business line, the stock could rally significantly from distressed levels—though the probability of success is low, the asymmetric payoff is high

As a SPAC trading near trust value with a filing delinquency, there may be a mispricing between the stock price and the trust value per share; if the delinquency is resolved and the SPAC liquidates, shareholders receive the trust value—this creates a potential arbitrage for investors with a detailed understanding of the trust terms

The stockholders' equity deficiency ($2.5M minimum) suggests TOMI needs a capital infusion; for investors with high risk tolerance, participating in a potential rights offering or private placement at distressed levels could yield significant returns if the company successfully restructures and remains listed

5 of 6 companies face material delisting risk with no visible catalysts for recovery; short sellers may find opportunities to profit from continued price declines, particularly for SOCIETY PASS (bankruptcy) and TOMI (dual deficiency), where the downside scenario is total equity loss

The next 60-day period (through mid-July 2026) is critical for Aimei Health's 10-Q filing; monitoring this event closely could signal whether the SPAC is pursuing a de-SPAC merger or liquidation, with significant price moves in either direction

6 delisting or compliance actions on a single day (May 19-20, 2026) represent a concentration of regulatory enforcement; compared to historical averages of 1-2 per day, this suggests Nasdaq is accelerating enforcement actions, potentially due to increased market volatility or a shift in regulatory priorities under new exchange leadership

4 of 6 companies (SOCIETY PASS, TOMI, Singularity Future, Socket Mobile) have been non-compliant since November 2025, indicating that the current enforcement cycle is targeting companies with chronic deficiencies rather than temporary shocks; this pattern suggests investors should avoid micro-cap stocks trading below $1.00 for extended periods, as the probability of delisting increases materially after 6 months

0 of the 6 filings reported insider transactions, despite 5 involving negative compliance events; this is a stark contrast to typical distressed scenarios where management might buy dips to signal confidence—the lack of insider purchases suggests either restricted trading windows, lack of liquidity among insiders, or rational reluctance to deploy capital into failing entities

Across all 6 filings, there were zero mentions of dividends, buybacks, or capital returns; this is consistent with companies in cash preservation mode, but also signals that these entities have no shareholder return programs, making them unattractive for income-focused or total-return strategies—investors are entirely reliant on capital appreciation for returns

SOCIETY PASS filed Chapter 11 on May 12 and received delisting notice on May 14, with trading suspended on May 21—a 9-day timeline from bankruptcy filing to delisting; this compressed timeline suggests Nasdaq may have streamlined procedures for de-listing bankrupt companies, reducing the typical grace period and increasing urgency for equity holders to exit positions quickly after a Chapter 11 filing

Trading suspension effective May 21, 2026; watch for Form 25-NSE filing and potential OTC trading initiation—equity holders should attempt to sell before suspension if still possible [May 20-21, 2026]

Must file Form 10-Q or submit a compliance plan by approximately July 18, 2026 (60 days from notice); watch for press releases regarding merger updates or filing status [Deadline: ~July 18, 2026]

Has 180 days to cure bid price deficiency (by November 16, 2026); watch for reverse split announcements, operational updates, or changes in share price that might indicate compliance trajectory [Deadline: November 16, 2026]

Second compliance period runs through November 16, 2026; monitor for at least 10 consecutive trading days with closing bid price at or above $1.00—any such streak would signal potential compliance [Ongoing through November 16, 2026]

Appeal process should be initiated within days; watch for hearing date announcements and any interim compliance measures—the dual deficiency makes this a higher-risk watch than single-issue cases [Immediate, hearing likely within 30-45 days]

After this cluster of 6 actions on May 19-20, monitor for additional delisting notices in the following weeks to determine if this is a one-time event or a broader crackdown—if the pace continues, it could signal a regime change in listing standards enforcement [Ongoing, next 2-4 weeks critical]

While compliance was regained, monitor for any subsequent resignations from the Audit Committee or board that could trigger another deficiency—the rapid resolution suggests strong governance, but the stock remains a micro-cap with associated volatility [Ongoing]